Skip to main content
Fig. 1 (abstract P-130). | BMC Proceedings

Fig. 1 (abstract P-130).

From: Abstracts from the 25th European Society for Animal Cell Technology Meeting: Cell Technologies for Innovative Therapies

Fig. 1 (abstract P-130).

a Built-in sequence database and automated sequence-processing pipeline of Genedata Bioprocessâ„¢. In the upper panel the alignment of IgG1 sequences plus graphical representation of potential liability motifs such as deamidation, oxidation, glycosylation motifs in the CDR3 sequence of candidates are shown. Here, for four IgG1 drug candidates an overview of potential molecule liabilities for the developability assessment using a traffic-light system is depicted (lower panel). b Traffic-light system for developability assessment of drug candidates using distinct cell lines. The outcome of a broad panel of analytical tests is displayed, it is based on thresholds set for individual test parameters. Here, the drug candidate TPP-84 produced in the cell line CLI-37 fulfills all desired developability criteria. c Visualized data refer to N-linked glycan analysis. Here, we show the degrees of afucosylation, galactosylation and sialyation for drug candidate molecule TPP-86 expressed in different CHO-K1 cell lines generated during a cell line development campaign. The cell line CLI-35 fulfills the desired glycosylation requirements (refer to panel b)

Back to article page